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Breast cancer patients’ clinical outcome measures are associated
with Src kinase family member expression
B Elsberger1, R Fullerton1, S Zino1, F Jordan2, TJ Mitchell1, VG Brunton3, EA Mallon4, PG Shiels1
and J Edwards*,1
1Western Inf irmary Glasgow, Section of Surgery, Division of Cancer Sciences and Molecular Pathology, Faculty of Medicine, Level 2, McGregor Building,
Dumbarton Road, Glasgow G11 6NT, UK; 2Western Inf irmary Glasgow, Division of Developmental Medicine Reproductive and Maternal Medicine,
Faculty of Medicine, Level 3, McGregor Building, Dumbarton Road, Glasgow G11 6NT, UK; 3Edinburgh Cancer Research Centre, University of Edinburgh,
Crewe Road, Edinburgh EH4 2XR, UK; 4Western Inf irmary Glasgow, Department of Pathology, Dumbarton Road, Glasgow G11 6NT, UK
BACKGROUND: This study determined mRNA expression levels for Src kinase family (SFK) members in breast tissue specimens and
assessed protein expression levels of prominent SFK members in invasive breast cancer to establish associations with clinical
outcome. Ki67 was investigated to determine association between SFK members and proliferation.
METHODS: The mRNA expression levels were assessed for eight SFK members by quantitative real-time PCR. Immunohistochemistry
was performed for c-Src, Lyn, Lck and Ki67.
RESULTS: mRNA expression was quantified in all tissue samples. SRC and LYN were the most highly expressed in malignant tissue. LCK
was more highly expressed in oestrogen receptor (ER)-negative, compared with ER-positive tumours. High cytoplasmic Src kinase
protein expression was significantly associated with decreased disease-specific survival. Lyn was not associated with survival at any
cellular location. High membrane Lck expression was significantly associated with improved survival. Ki67 expression correlated with
tumour grade and nuclear c-Src, but was not associated with survival.
CONCLUSIONS: All eight SFK members were expressed in different breast tissues. Src kinase was highest expressed in breast cancer
and had a negative impact on disease-specific survival. Membrane expression of Lck was associated with improved clinical outcome.
High expression of Src kinase correlated with high proliferation.
British Journal of Cancer (2010) 103, 899–909. doi:10.1038/sj.bjc.6605829 www.bjcancer.com
Published online 17 August 2010
& 2010 Cancer Research UK
Keywords: Src kinase family members; breast cancer; quantitative real-time PCR; immunohistochemistry; disease-specific survival























































In 1911 Peyton Rous discovered v-Src, an avian retrovirus, causing
transmissible sarcoma in chicken. This was followed by the
discovery of c-Src, the human cellular counterpart of v-Src
(Stehelin et al, 1976). It has now been established, that c-Src is
part of a family of non-receptor tyrosine kinases containing eight
family members expressed in mammalian cells that are involved
with cancer progression and invasion (Brown and Cooper, 1996;
Manning et al, 2002). c-Src, Fyn and Yes are widely expressed,
whereas Lck, Hck, Fgr, Blk and Lyn are more selectively expressed
in specific tissues (Irby and Yeatman, 2000; Palacios and Weiss,
2004). All Src family kinase (SFK) members have a similar
structure: a C-terminal tail, four conserved Src homology domains
and a unique amino-terminal domain that varies between the
family members (Martin, 2001; Engen et al, 2008).
Src kinase has been investigated for a long time in a variety of
solid tumours. Data from human cancer tissues have further
defined the role of Src in tumour development in a more clinically
relevant setting. Elevated levels of Src or SFKs have been detected
in a range of human solid tumours, including glioblastoma (Kleber
et al, 2008), cancers of the prostate (Tatarov et al, 2009), breast
(Verbeek et al, 1996), pancreas (Fu et al, 2006), colon (Bolen et al,
1987) and lung (Masaki et al, 2003). In vitro evidence for a role
for c-Src in breast cancer is convincing, but currently hardly
supported by translational clinical studies. In breast cancer, Src
activity and distribution might impact on resistance to endocrine
therapy in patients with oestrogen receptor/progesterone recep-
tor (ER/PgR)-positive disease. Elevated c-Src activity promotes
cellular invasion and motility in tamoxifen-resistant breast cancer
cells (Hiscox et al, 2006) and provides a link between the HER
family and steroid receptors (Yeatman, 2004; Likhite et al, 2006).
Campbell et al (2008) illustrated that activated Src localised to
the nucleus was significantly associated with improved overall
survival and a lower recurrence rate during tamoxifen treatment
of ER/PgR-positive tumours.
Other Src family members have also been linked with breast
cancer. Again, there is little published evidence on the role of other
Src family members in clinical breast cancer specimen. It is well
established that Lyn has an important role in leukaemia. This has
been suggested by several studies (Roginskaya et al, 1999; Wilson
et al, 2002; Warmuth et al, 2003). Lyn is also involved in the
development of certain solid tumours. Colon carcinoma cells use
Lyn in the activation of the Akt (anti-apoptotic) pathway, and
chemoresistant colonic cancer cells displayed elevated Lyn kinase
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activity (Bates et al, 2001). Inhibition of Lyn in prostate cancer cell
lines resulted in reduced proliferation in vitro and in prostatic
cancer xenograft models (Goldenberg-Furmanov et al, 2004).
A recently published study shows that Lyn was associated with
shorter overall survival, and that RNAi knockdown of Lyn in
breast cancer cell lines inhibited cell migration and invasion, but
not proliferation (Choi et al, 2010). Microarray studies have
demonstrated that Lyn is induced in models of endocrine
resistance (Gee et al, 2006) and Lck is implicated in hypoxia-
induced breast cancer progression (Chakraborty et al, 2006).
The aim of the present study was therefore to establish mRNA
expression levels for SFK members in human breast tissue and,
subsequently, to assess protein expression of the most abundantly
expressed SFK members, in a larger cohort of invasive breast
cancer patients, to determine whether these are linked to clinical
outcome measures.
MATERIALS AND METHODS
Patients
The study was granted approval by the local ethics committee for
both the cohort used to determine mRNA expression (reverse
transcriptase PCR (RT–PCR) cohort) and the cohort used to
determine protein expression (immunohistochemistry (IHC) cohort).
The RT–PCR cohort contained 139 patients and was subdivided
into Patient group 1 (M), consisting of malignant tissue samples
taken from 81 breast cancer patients at the time of primary tumour
resection. All patients were diagnosed with invasive breast
carcinoma between 1987 and 2005 in the Greater Glasgow area.
Patient group 2 (NM) included non-malignant tissue samples from
48 breast cancer patients taken from disease-free areas of
mastectomy resection specimens. Patient group 3 (N) comprised
of 10 normal breast tissue specimens obtained from reduction
mammoplasties. The ER status was determined in a routine
diagnostic laboratory.
The IHC cohort is completely distinct from the PCR cohort with no
overlapping patients. All patients in the IHC cohort were diagnosed
with primary operable breast cancer between 1980 and 1999 and
received standard adjuvant treatment according to protocols at the
time of diagnosis. Only patients with full clinical data available were
included in analysis. All tissue samples were taken at the time of
surgical resection, assessed and determined by a pathologist.
Quantitative reverse transcriptase PCR
Tissue processing After resection of the primary tumour,
representative parts of malignant and non-malignant breast tissue
were identified by a pathologist, snap frozen and stored in liquid
nitrogen. Normal breast tissue was selected and taken from
different sites of breast reduction specimens.
RNA isolation Total mRNA was extracted from 50 to 75mg of
breast tissue using the TRIZOL (Invitrogen, Paisley, UK) method
according to manufacturer’s protocol. RNA quantity and quality
was assessed by UV spectrometry (GeneQuant machine, GE
Healthcare, Little Chalfont, UK) and by examination of rRNA
bands after agarose gel electrophoresis. Only samples that showed
both 18S band and a stronger expressed 28S band were used.
cDNA synthesis A measure of 1000 ng of RNA was treated with
RNAse-free DNAse and removal reagent kit (Applera, Warrington,
UK), and random hexamer primers (50 ng) were used for First
Strand cDNA synthesis using SuperScript II RT (Invitrogen).
Before using cDNA for PCR amplification, 2U of RNase H
(Applera) were added to samples and incubated for 20min at 371C.
Quality of cDNA was assessed by using a PCR control run with
human b-actin. Product bands were assessed by examination of
agarose gel electrophoresis. Only samples that showed equal
product bands at 330 bp were included in this study.
Quantification of mRNA Real-time quantitative PCR was per-
formed using an ABI Prism 7900 Sequence Detection System
(Applied Biosystems, Warrington, UK) and TaqMan Gene
Expression Assays (Applied Biosystems) (Table 1). For TaqMan
Gene Expression assays, the manufacturer’s protocol with
recommended 40 rounds of amplification was used. Thermal
cycler conditions were 501C for 2min, 951C for 10min, followed by
40 951C for 15 s and 601C for 1min. Product melting curve
analysis and gel electrophoresis experiments were used to ensure
that only one product of the expected size was amplified.
Negative controls for each primer were included in each run.
Quantitative values were obtained from the threshold cycle (Ct value)
at which an increase in TaqMan probe fluorescent signal was asso-
ciated with an exponential increase of each individual PCR product
reaching a fixed threshold value. Each individual primer had a fixed
threshold Ct value. These fixed threshold values were used for every
cDNA sample (Table 1).
To enable comparison of different mRNA expression levels,
their relation to the average expression level of housekeeping gene
HPRT (hypoxanthine–guanine phosphoribosyltransferase) was
evaluated. Data were analysed using the sequence detection
software, which calculates the Ct value. The expression of the
target assay was normalised by subtracting the Ct value of the
housekeeping gene from the Ct value of the relevant target assay.
The fold increase, relative to the control, was obtained by using the
formula 2DCt, and then expressed as a percentage ( 100). All
samples were measured in duplicates.
Table 1 Intron-skipping primers used for real-time PCR, their fixed threshold Ct values and expression levels in different breast tissue
Gene
Gene expression
assay ID
Threshold (Ct)
value
Expression
levels in M
Expression
levels in NM
Expression
levels in N P-values
SRC Hs00178494_m1 0.28263707 9041 9252 9493 0.976
LYN Hs00176719_m1 0.34538345 7233 8922 10 521 0.076
LCK Hs00178427_m1 0.26297827 655 217 255 o0.001
FYN Hs00176628_m1 0.27740355 2245 5293 25 484 o0.001
FGR Hs00178340_m1 0.22993330 1144 1275 1072 0.943
HCK Hs00176654_m1 0.37934458 1815 2673 1712 0.070
BLK Hs00176441_m1 0.23531063 208 161 234 0.114
YES Hs00736972_m1 0.14854589 2142 499 3312 o0.001
HPRT 4310890E 0.25742040 NA NA NA NA
Abbreviations: M¼ invasive breast cancer; N¼ normal tissue; NA¼ not applicable; NM¼ non-malignant. The table reveals details of each individual Src kinase family member
and the housekeeping gene HPRT. Expression levels of Src kinase family members in different breast tissue types are stated as medians. P-values express alterations of expression
in the different breast tissue types (Kruskal –Wallis test). Bold typeface is used to highlight significant P-values.
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Tissue microarray construction
Tissue microarrays (TMAs) were already available for use in this study.
The pathologist identified 0.6mm2 cores of breast cancer tissue.
The TMA blocks were constructed in triplicates (Tovey et al, 2005).
Immunohistochemistry
Staining for ER, PgR and HER2 had been previously performed for
the cohort (Tovey et al, 2005). SFK member expression was
investigated using antibodies for c-Src (36D10, Cell Signalling
Technology, Danvers, MA, USA), Lyn (BD Biosciences, Oxford,
UK) and Lck (Cell Signalling Technology). Ki67 antigen MIB-1
(DAKO, Ely, UK) was used to determine proliferation status. All
SFK antibodies used were tested by western blot to ensure that
only one single band of the appropriate size was observed. Tissue
sections were dewaxed and rehydrated through graded alcohol.
c-Src antibody was incubated in a preheated antigen retrieval
solution (citrate buffer, pH 6.0, Vector Laboratories, Burlingame,
CA, USA), whereas Lyn, Lck and Ki67 antibodies were incubated in
TE Buffer (pH 8.0, 5mM Tris, VWR, Lutterworth, UK and 1mM
EDTA, Sigma, Dorset, UK). Antigen retrieval was performed by
heating tissue sections under pressure for 5min in a microwave.
Endogenous peroxidase activity was destroyed by incubation in
0.3% hydrogen peroxide (H2O2) (c-Src), 1% H2O2 solution (Lyn)
and 3% H2O2 solution (Lck, Ki67), and non-specific binding
blocked by incubating in 1.5% normal horse serum (c-Src) and 5%
normal horse serum (Lyn, Lck and Ki67) (Vector Laboratories) for
20min at room temperature. Primary antibody was applied and
tissue incubated with c-Src (1 : 200 dilution, 4.32 mgml1), Lck
(1 : 50, 0.76 mgml1) and Ki67 (1 : 150, 533.33 mgml1) for 60min at
room temperature. Lyn was incubated overnight at 41C (1 : 5,
50 mgml1). Signal was amplified and visualised using the DAKO
Envision Kit (DAKO Cytomation, Glostrip, Denmark) and the
chromagen 3,30-diaminobenzidine (DAB, Vector Laboratories).
Sections were counterstained, dehydrated and mounted. In each
run, a positive control and a negative isotype-matched control was
included to ensure no false-positive staining.
Scoring
The SFK member expression of each core (three per tumour
specimen) was assessed using the weighted histoscore method
(H-score method (Kirkegaard et al, 2006)). Ki67 was scored counting
positive and negative nuclei in the tumour specimen and then the
percentage of positive cells was calculated (Ki67 labelling index
(Canna et al, 2008)). Agreement between observers was excellent
and measured in interclass correlation coefficient (ICCC). All ICCC
scores were above 0.8. The observers were blinded to the clinical
outcome of the patients.
Statistical analysis
Differences in expression levels were analysed using the Mann–
Whitney U-test or Kruskal–Wallis test, including a Wilcoxon-type
test for trends, when appropriate. Associations between contin-
uous variables were assessed with the Spearman rank test. Disease-
specific survival rates were generated using the Kaplan–Meier
method. The log-rank test was used to compare significant
differences between subgroups using univariate analysis. Multi-
variate stepwise Cox-regression analysis was performed to identify
factors that were independently associated with disease-specific
death. A stepwise backward procedure was used to derive a final
model of the variables that had a significant independent
relationship with survival. To remove a variable from the model,
the corresponding P-value had to be 40.05.
Inter-relationships between clinical parameters, ER, PgR and
HER2 status were calculated using the w2-test. Because of the
number of statistical comparisons, a P-value of o0.01 was
considered to be significant. Data are expressed as median and
range. The statistical analyses were performed using a statistical
software package (SPSS 15.0 Inc, Chicago, IL, USA).
RESULTS
Clinicopathological details of cohort one
The PCR cohort consisted of 81 invasive breast cancers (M),
48 non-malignant (NM) and 10 normal (N) breast tissue samples.
Median age of the breast cancer patients was 61 years (IQR 49–74).
Median size of breast cancer was 30mm (IQR 20–42). In all, 40%
of the specimens were pathologically graded G2 and 48% G3.
A total of 52 breast cancer patients were ER positive compared
with 29 ER-negative patients. A total of 55% of breast cancer
patients were axillary lymph node positive. Median NPI was 4.6
(IQR 4.3–5.4). Patients underwent either breast-conserving wide
local excision (16%) or a radical mastectomy (67%; the rest 17%
unknown). Axillary dissection was performed in 83% of cases. At
time of analysis, 37 out of 79 patients were deceased. Of those 37
patients, 18 died of breast cancer-related causes. Median follow-up
time was 5.6 years (IQR 1.8–17.6).
Median age of breast cancer patients, from whom a non-
malignant specimen of breast tissue was obtained, was also 61
years (IQR 52–71). Of those patients, 63% were ER positive and
17% ER negative. ER status was not significantly different between
tissue types (P¼ 0.847). Median age of breast reduction patients
supplying normal breast tissue was 37 years (IQR 33–48).
mRNA expression levels in human breast tissue
Expression levels for SFK member were quantified in all tissue
samples (Table 1). BLK was the least-expressed SFK member in all
breast tissues. No change in the level of SRC expression was
observed between tissue types (P¼ 0.976) (Figure 1A), whereas
LCK, FYN and YES showed significant changes in expression
between different breast tissue types (Table 1). Figure 1A–H
demonstrates the data range of all SFK members.
SFK member expression in breast cancer specimens The most
highly expressed SFK members in malignant breast tissue were
SRC and LYN. Higher expression levels of LCK were observed in
invasive breast cancers compared with non-malignant and normal
breast tissue (Po0.001) (Figure 1C). Interestingly, LCK was 14-fold
less expressed than SRC. It also was the only SFK member that
showed a difference in expression levels between ER-negative
and ER-positive patients. LCK was more highly expressed in
ER-negative patients, compared with ER-positive patients (Figure 2A).
All SFK members correlated with SRC expression. The strongest
correlation with SRC expression was detected with LYN (Po0.001,
c.c. 0.570) and the weakest with YES (P¼ 0.030, c.c. 0.242). Survival
analysis was completed for all SFK members. Only SRC was
significantly associated with decreased disease-specific survival in
ER-positive breast cancer patients (P¼ 0.012; Figure 2B) compared
with ER-negative patients (P¼ 0.923, Figure 2C). Patients with
high SRC mRNA expression had a median survival of 4.5 years
(IQR 2.7–6.3) compared with those with low expression, with a
median survival of 11.6 years (IQR 6.9–13.3) (P¼ 0.012).
SFK member expression in non-malignant breast tissue As
observed within the invasive breast cancer specimen, SRC and LYN
were the highest-expressed SFK members in non-malignant breast
tissue. YES was least expressed in non-malignant breast tissue,
compared with malignant and normal breast tissue (Po0.001)
(Figure 1H). As with the invasive breast cancer specimens, all other
SFK members correlated with SRC expression. Again the strongest
SRC expression correlation was with LYN (Po0.001, c.c. 0.799)
(Figure 2D) and the weakest with YES (P¼ 0.027, c.c. 0.326).
Src kinase family member expression
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SFK member expression in normal/breast reduction tissue FYN
was the most highly expressed SFK member in normal tissue. It
was significantly higher expressed than any other SFK members:
2.7-fold higher than SRC and 100-fold higher than LCK. Highest
expression levels of FYN were observed in normal tissue compared
with non-malignant and lowest in invasive breast cancer speci-
mens (Po0.001) (Figure 1D). No correlations between SRC and
SFK members were observed in normal breast tissue.
P = 0.976SRC LYN P = 0.076
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Figure 1 Graphs for cohort one (mRNA). (A–H) mRNA expression of Src kinase family members in different breast tissue. (A) Unchanged SRC mRNA
expression levels in normal, non-malignant and malignant breast specimens (P¼ 0.907). (B) LYN mRNA expression levels in normal, non-malignant
and malignant breast specimens (P¼ 0.076). (C) Different LCK mRNA expression in normal, non-malignant and malignant breast specimens (Po0.001).
(D) Altered FYN mRNA expression levels in normal, non-malignant and malignant breast specimens (Po0.001). (E) FGR mRNA expression levels in
normal, non-malignant and malignant breast specimens (P¼ 0.943). (F) HCK mRNA expression levels in normal, non-malignant and malignant breast
specimens (P¼ 0.070). (G) BLK mRNA expression levels in normal, non-malignant and malignant breast specimens (P¼ 0.114). (H) YES mRNA expression
in normal, non-malignant and malignant breast specimens (Po0.001).
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Clinicopathological details of cohort two
The second cohort consisted of 274 breast cancer patients (180 ER
positive and 94 ER negative) (Table 2). Median age was 58 years
(IQR 51–68). Median tumour size was 20mm (IQR 15–30).
Majority of the cancer specimens were pathologically graded as G2
(45%) and G3 (48%). A total of 49% of the patients were axillary
lymph node positive. Mean patient follow-up was 6.3 years
P = 0.03LCK mRNA Src P = 0.012
Low expression
n = 8
n = 52n = 29 High expression
n = 17
ER pos
P = 0.923
p<0.001, c.c. 0.799
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Figure 2 (A) The difference between LCK mRNA expression in ER-negative compared with ER-positive breast cancer patients (P¼ 0.030).
(B) A Kaplan–Meier survival graph for mRNA expression of SFK member SRC in ER-positive patients (P¼ 0.012). (C) A Kaplan–Meier survival graph for
mRNA expression of SFK member SRC in ER-negative patients (P¼ 0.923). (D) The correlation of SRC mRNA expression with LYN in the non-malignant
PCR cohort (Po0.001, c.c. 0.799).
Table 2 Impact of clinicopathological factors and protein expression/activation on patient survival
Total patient cohort (274 patients) Univariate analysis Multivariate analysis
Variables Numbers P-value HR IQR P-value HR IQR
Age (o50/450 years) 68/206 0.365 1.3 0.7–2.4
Tumour type (ductal/lobular/tubular/others) 260/9/2/3 0.774 0.7 0.3–1.6
Grade (G1/G2/G3) 20/122/132 0.030 1.8 1.2–2.8 0.659
Size (o20/20–50/450mm) 111/148/15 o0.001 3.8 2.4–6.0 o0.001 12.2 5.4–27.8
Lymph node (positive/negative) 132/142 o0.001 2.5 1.5–4.1 0.018 1.9 1.1–3.2
ER status (positive/negative) 180/94 o0.001 2.3 1.4–3.8 o0.001 2.5 1.5–4.1
PgR status (positive/negative) 132/140 0.009 1.9 1.2–3.2 0.579
HER2 status (positive/negative) 38/236 0.001 2.5 1.4–4.3 0.281
c-Src nuc expression (positive/negative) 129/145 0.399 1.2 0.7–2.0
c-Src cyto expression (positive/negative) 118/156 0.013 1.8 1.1–3.0 0.131
c-Src memb expression (positive/negative) 113/161 0.787 1.9 1.2–3.2
Lyn nuc expression (positive/negative) 66/116 0.742 0.9 0.5–1.7
Lyn cyto expression (positive/negative) 61/121 0.997 1.0 0.5–1.9
Lyn memb expression (positive/negative) 9/173 0.825 1.1 0.3–3.7
Lck nuc expression (positive/negative) 116/158 0.148 0.7 0.4–1.1
Lck cyto expression (positive/negative) 117/157 0.964 1.0 0.9–1.0
Lck memb expression (positive/negative) 14/260 0.039 0.1 0.01–4.0 0.972
Ki67 (o5/5–20/420) 261/91/30 0.254 1.0 0.5–1.9
Abbreviations: c-Src¼ total Src kinase; c-Src cyto¼ c-Src cytoplasmic expression; c-Src memb¼ c-Src membrane expression; c-Src nuc¼ c-Src nuclear expression;
ductal¼ ductal carcinoma; ER¼ oestrogen receptor; Grade¼ Bloom and Richardson grade; HER2¼ human epidermal growth factor receptor 2; HR¼ hazards ratio;
IQR¼ interquartile range; Ki67¼ Ki67 proliferation score, lowo5, moderate 5–20, high420; Lck cyto¼ Lck cytoplasmic expression; Lck memb¼ Lck membrane expression;
Lck nuc¼ Lyn nuclear expression; Lyn cyto¼ Lyn cytoplasmic expression; Lyn memb¼ Lyn membrane expression; Lyn nuc¼ Lyn nuclear expression; others¼mucinous, mucoid
and micropapillary carcinoma; PgR¼ progesterone receptor; tubular¼ tubular carcinoma. The table shows an overview of the full patient cohort’s characteristics. Each clinical and
pathological parameter was correlated to disease-specific survival (P-values). Bold typeface is used to highlight significant P-values.
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(minimum follow-up was 3.7 years and the maximum follow-up
was 19.5 years). A total of 17 patients were lost to follow-up.
During this period, 65 patients died of their cancer and a further
27 patients died of inter-current disease. In all, 171 patients were
still alive at time of last follow-up. Correlations between the clinico-
pathological characteristics of this cohort are shown in Table 2.
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Protein expression levels of SFK members in invasive
breast cancers
c-Src kinase Each cellular location was independently assessed for Src
kinase expression levels. A total of 48% of tumours exhibited nuclear
expression, 61% cytoplasmic and 41% membrane (Figure 3A–C).
Tumours were subdivided into those with high (above the median)
or low (below or equal to the median) expression. The w2-analysis
demonstrated that grade and HER2 status positively correlated
with cytoplasmic c-Src expression (Table 3). The ER and PgR
status correlated negatively with cytoplasmic and membrane c-Src
expression (Table 3). c-Src expression at each cellular location
correlated with HER2 status (Table 3) and with each other
(Table 4). On univariate analysis, neither membrane nor nuclear
c-Src expression was associated with disease-specific survival. High
cytoplasmic c-Src kinase expression was significantly associated with
shorter disease-specific survival (P¼ 0.013; Figure 4A), but was not
independent in multivariate analysis (Table 2). Those patients with
high cytoplasmic c-Src expression had a median survival of 12.2
years (IQR 10.0–14.4) compared with those with low expression,
with median survival of 15.6 years (IQR 13.9–17.3).
Lyn Owing to tissue limitations, only 68% of the tumours
previously available for analysis were able to be stained for Lyn
expression (186 of 274). A total of 34% of Lyn expression was
observed in the nucleus, 36% in the cytoplasm and only 5% in the
membrane (Figure 3D–F). On univariate analysis, there was no
association noticed between Lyn expression and disease-specific
Table 3 The interrelationships between the clinicopathological characteristics of patients with breast cancer, Src kinase family member expression
and Ki67
Total patient cohort (274 patients) v2 P-values
Variables Numbers
c-Src
nuc
c-Src
cyto
c-Src
memb
Lyn
nuc
Lyn
cyto
Lyn
memb
Lck
nuc
Lck
cyto
Lck
memb Ki 67
Age (o50/450 years) 68/206 0.786 0.638 0.798 0.259 0.027 0.297 0.639 0.927 0.024 0.965
Tumour type (duct/lob/tub/others) 260/9/2/3 0.788 0.431 0.446 0.642 0.547 0.492 0.375 0.032 0.842 0.360
Grade (G1/G2/G3) 20/122/132 0.021 0.001 0.017 0.019 0.632 0.991 0.034 0.543 0.741 0.006
Size (o20, 20–50, 450mm) 111/148/15 0.421 0.037 0.007 0.029 0.832 0.115 0.892 0.580 0.926 0.186
Lymph node (positive/negative) 132/142 0.732 0.359 0.589 0.123 0.200 0.247 0.957 0.308 0.311 0.590
ER status (positive/negative) 180/94 0.043 o0.001a 0.006a 0.133 0.122 0.876 0.001a 0.600 0.118 0.997
PgR status (positive/negative) 132/140 0.184 0.002a 0.001a 0.339 0.015 0.048 0.097 0.036 0.090 0.280
HER2 status (positive/negative) 38/236 0.007 o0.001 0.007 0.733 0.836 0.772 0.168 0.085 1.000 0.200
Abbreviations: c-Src¼ total Src kinase; c-Src cyto¼ c-Src cytoplasmic expression; c-Src memb¼ c-Src membrane expression; c-Src nuc¼ c-Src nuclear expression; duct¼ ductal
carcinoma; ER¼ oestrogen receptor; Grade¼ Bloom and Richardson grade; HER2¼ human epidermal growth factor receptor 2; Ki67¼ Ki67 proliferation score, low o5,
moderate 5–20, high 420; Lck cyto¼ Lck cytoplasmic expression; Lck memb¼ Lck membrane expression; Lck nuc¼ Lyn nuclear expression; lob¼ lobular carcinoma;
Lyn cyto¼ Lyn cytoplasmic expression; Lyn memb¼ Lyn membrane expression; Lyn nuc¼ Lyn nuclear expression; others¼mucinous, mucoid and micropapillary carcinoma;
tub¼ tubular carcinoma. aNegative correlation. Bold typeface is used to highlight significant P-values.
Figure 3 Images of immunohistochemistry (IHC) for each antibody. (A–C) Breast cancer tissue stained with c-Src antibody (1 : 200, Cell Signalling).
(A) An overview of a 0.6mm core of the breast cancer tissue microarray, demonstrating no stromal staining, weak cytoplasmic, none and weak nuclear
staining; magnification 10. (B) Weak cytoplasmic, none and weak nuclear and weak membrane staining; magnification 100. (C) Negative staining
of stroma and tumour tissue; magnification 100. (D–F) Breast cancer tissue stained with Lyn antibody (1 : 5, BD Biosciences). (D) An overview of a
0.6mm core of the breast cancer tissue microarray, demonstrating no stromal staining, weak cytoplasmic, none and weak nuclear staining; magnification
10. (E) Weak cytoplasmic, none and weak nuclear staining; magnification 100. (F) No stromal staining, weak cytoplasmic, none, weak and moderate
nuclear staining; magnification 100. (G– I) Breast cancer tissue stained with Lck antibody (1 : 50, Cell Signalling). (G) Strong staining of tonsil with Lck
(positive control); magnification 2. (H) Negative staining of stroma and tumour tissue; magnification 100. (I) Weak cytoplasmic and weak membrane
staining; magnification 100. (J–M) Ki67 staining of invasive breast cancer specimen (1 : 150, DAKO). (J) Negative staining of stroma and tumour tissue;
magnification 100. (K) Ki67 staining classified as weak staining; magnification 100. (L) Ki67 staining classified as moderate staining; magnification 100.
(M) Ki67 staining classified as strong staining; magnification 100.
Table 4 The interrelationships between Src kinase family member expression and Ki67
Total patient cohort (274 patients) v2 P-values
Variables Numbers
c-Src
cyto
c-Src
memb
Lyn
nuc
Lyn
cyto
Lyn
memb
Lck
nuc
Lck
cyto
Lck
memb Ki67
c-Src nuc (positive/negative) 129/145 o0.001 o0.001 0.163 0.646 0.917 0.328 0.461 0.701 0.001
c-Src cyto (positive/negative) 118/156 o0.001 0.621 0.579 0.780 0.299 0.508 0.934 0.110
c-Src memb (positive/negative) 113/161 0.691 0.497 0.410 0.274 0.064 0.017 0.110
Lyn nuclear (positive/negative) 66/116 o0.001 0.345 0.016 0.975 0.534 0.081
Lyn cyto (positive/negative) 61/121 o0.001 0.424 0.067 0.032 0.598
Lyn memb (positive/negative) 9/173 0.282 0.726 0.053 0.010
Lck nuclear (positive/negative) 116/158 o0.001 0.001 0.045
Lck cyto (positive/negative) 117/157 o0.001 0.572
Lck memb (positive/negative) 14/260 0.506
Abbreviations: c-Src¼ total Src kinase; c-Src cyto¼ c-Src cytoplasmic expression; c-Src memb¼ c-Src membrane expression; duct¼ ductal carcinoma; c-Src nuc¼ c-Src nuclear
expression; Grade¼ Bloom and Richardson grade; Ki67¼ Ki67 proliferation score lowo5, moderate 5–20, high420; Lck cyto¼ Lck cytoplasmic expression; Lck memb¼ Lck
membrane expression; Lck nuc¼ Lyn nuclear expression; lob¼ lobular carcinoma; tub¼ tubular carcinoma; Lyn cyto¼ Lyn cytoplasmic expression; Lyn memb¼ Lyn membrane
expression; Lyn nuc¼ Lyn nuclear expression; others¼mucinous, mucoid and micropapillary carcinoma. Bold typeface is used to highlight significant P-value.
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survival at any cellular location (Table 2). The w2-analysis showed no
significant correlations between Lyn expression, clinicopathological
features of the cohort or expression level and location of other SFK
members (Tables 3 and 4).
Lck Lck expression was observed to be 42.5% in the breast
cancers nucleus, 42.5% in the cytoplasm and 5% in the membrane
(Figure 3G–I). The w2-analysis showed that nuclear Lck expression
correlated negatively with ER status (P¼ 0.001; Table 3, Figure 4B).
Lck expression at all cellular locations correlated with each other.
On univariate analysis, cytoplasmic and nuclear Lck expression
was not associated with disease-specific survival (Table 2), whereas
membrane Lck expression was significantly associated with
disease-specific survival (P¼ 0.039; Figure 4C). None of patients
expressing Lck on the cell membrane died of breast cancer. Median
follow-up for patients with positive Lck staining of the membrane
was 7.8 years (s.d.±4.5) and for patients without staining, 6.0
years (s.d.±3.5).
Ki67 As observed before with Lyn, Ki67 immunohistochemistry
was obtained from 71% (194 of 274) of the TMA tumours because
of tissue limitation. Median Ki67 score was 3.8 (IQR 0–9.8). Scores
were classified into three groups (low-medium-high). A total of
59% of the tumour specimens had a low proliferation rate, with a
Ki67 score of o5, 32% had a medium proliferation rate of 5–20
and only 9% of the tumours had a high proliferation rate of 420
(Figure 3J–M). The w2-analysis demonstrated that Ki67 scores
correlated positively with tumour grade (Table 3) and nuclear
c-Src (P¼ 0.001). On univariate analysis, Ki67 score was not
associated with disease-specific survival.
The relationship between all family members and clinical
parameters is shown in Figure 5.
DISCUSSION
The SFK members are expressed in various cell types and tissues
(Irby and Yeatman, 2000) and involved in cancer progression, via
transduction of signals for cell growth, differentiation and survival,
influencing cellular adhesion, migration and invasion (Brown and
Cooper, 1996). However, there is little translational evidence of
SFK member expression in breast tissue. We have investigated
expression levels for eight SFK members in normal, non-malignant
and malignant breast tissue. Interestingly, SRC expression levels
were unchanged between the tissue types, despite being the
highest-expressed SFK member in malignant and non-malignant,
but not in normal breast tissue. SRC also was the only SFK member
that was significantly associated with patients’ survival. Owing to
small patient numbers in the PCR cohort, the study to investigate
the role of Src was expanded into a larger cohort of formalin-fixed
paraffin-embedded specimens (IHC cohort). High expression of
cytoplasmic c-Src was associated with shorter disease-specific
survival, increasing grade, tumour size, ER negativity and HER2
positivity. These findings are consistent with our previous results
(Elsberger et al, 2009), with c-Src being associated with more
aggressive growth in cancer cell lines (Hynes, 2000; Frame, 2002).
We observed that Ki67 proliferation index correlated positively
with c-Src nuclear expression, but not with c-Src cytoplasmic
expression. This suggests that c-Src may have multiple roles within
the cell depending on cellular location. It was not surprising to find
that Ki67 was positively correlating with grade of the breast cancers.
LYN was also expressed at high mRNA levels in M and NM
tissue. However, no associations with clinicopathological features
and survival were noted in both cohorts. Other studies report that
Lyn has a part in developing chemoresistance of colon cancer (Bates
et al, 2001), progression of prostate tumours (Park et al, 2008)
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Figure 4 Kaplan–Meier survival graphs for Src kinase family member expressions in cohort two/IHC cohort (n¼ 274). (A) Kaplan–Meier survival graph
for cytoplasmic c-Src (P¼ 0.013). (B) Boxplot displaying nuclear Lck protein expression difference in ER-negative and -positive breast cancer patients
(P¼ 0.001). (C) Kaplan–Meier survival graph of membranous Lck (P¼ 0.039).
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and leukaemia (Lee et al, 2008). The latter is not surprising, as
Lyn is associated with a number of haematopoietic cell surface
receptors, cytokine receptors and is a key mediator in several
pathways of B-cell activation (Hibbs and Dunn, 1997). These
observations are congruent with a role for Lyn associated with the
development of chemoresistance. This study does not use any
hormone-resistant or chemoresistant tumours; only tumours
obtained at primary diagnosis. In the RT–PCR cohort, LCK
mRNA expression in invasive breast cancer was 14-fold less than
SRC and was associated with improved disease-specific survival in
the IHC cohort. Surprisingly, this was reverse to the observation
made with c-Src. Lck membrane expression was not associated
with patient mortality. A similar immunohistochemistry study
(Elsberger et al, 2009), investigating the different phosphorylation
sites of Src, demonstrated that phosphorylation site Y215 was
associated with improved disease-specific survival. With the
knowledge that phosphorylation antibodies are able to detect
other SFK members, we hypothesise that the Y216Src antibody
used could have identified Lck as the other SFK member associated
with good clinical outcome. However, this observation with Lck
membrane expression and good prognosis was only observed in a
small number of patients. Therefore, further analysis in a much
larger cohort is required to verify these results.
LCK mRNA expression was found to be higher in ER-negative
compared with ER-positive breast cancer samples. This was not
reproducible in the IHC cohort. Nuclear Lck protein expression
was higher expressed in the ER-positive breast cancer patients.
Interestingly, survival analysis with high nuclear Lck expression
displayed a trend to better clinical outcome of ER-positive
compared with ER-negative patients within the first 5 years after
diagnosis (data not shown). These findings are consistent with
results reported by Rody et al (2009), showing that Lck was
associated with improved disease-free survival within the
ER-positive and ER/HER2-positive breast cancer subgroup. It is
unclear whether this discrepancy between mRNA and protein
expression is based on using different patient cohorts or altered
transcription from RNA level to protein synthesis and expression.
As Lck is known to be involved in T-cell proliferation (Palacios
and Weiss, 2004), it was hypothesised that expression of this gene
was linked with the presence of lymphocyte infiltration within the
tumour and interacting with it. Results of this study demonstrated
that Lck is expressed within the tumour, providing evidence that
Lck itself may be involved with signal transduction in the tumour.
Other studies suggest that Syk, a member of another non-receptor
tyrosine family, is involved in hypoxia-driven tumour progression
via cross-talk to Lck in the nucleus (Chakraborty et al, 2006).
Lck has been implicated in the mitochondrial apoptosis pathway
by controlling the expression of pro-apoptotic factor Bak (Samraj
et al, 2006). Cell line experiments have shown that Lck defici-
ency resulted in resistance to anticancer drug-induced apoptosis.
T-lymphoma cells lacking Lck have shown marked resistance to
apoptosis reduction on exposure to ionising radiation (Belka et al,
1999). A more recent study from the same group adjusted their
previous findings that not just the lack of Lck caused pronounced
apoptosis resistance in response to stimuli of the intrinsic pathway
but the additional loss of Bak was responsible for reduced sensitivity
(Rudner et al, 2009). Decreased levels of other pro-apoptotic Bcl-2
family members, for example, Bax, have been shown to correspond
to shorter survival in women with metastatic breast cancer. However,
as yet no significant correlation between Bak and clinical outcome
has been seen within breast cancer (Reed, 1999).
This study established that all SFK members were expressed in
normal, non-malignant and malignant breast tissue. Quantitative
real-time PCR results showed equal SRC mRNA expression within
the different breast tissue types. However, this method does not
provide details regarding cellular location of Src kinase. Despite
two dissimilar cohorts of breast cancer patients and different
investigation methods, Src kinase was associated with poorer
survival outcome.
One major problem still remains: how to assess which tumours
will respond to Src inhibitors, so that those patients can be selected
who will probably benefit most from the treatment. Applicability
of microarray gene analysis in the clinical setting is now being tested
after identifying a gene signature that was able to predict response
to dasatinib in cell lines (Huang et al, 2007). Response rate with
molecular target therapy in unselected patient groups have been
very modest so far, and this most likely indicates that in most solid
tumours no single molecular event drives tumourigensis. The need
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Figure 5 Schematic representation of correlations between clinicopathological features of the IHC cohort, SFK protein expression and cellular location.
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for new predictive and prognostic indicators is clear, especially in
the currently difficult-to-treat patient subgroups such as ER/PgR-
negative and/or HER2-positive patients. The results of this study
highlight an exciting area for future research in terms of predicting
survival and the mechanisms of how this occurs.
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